In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous route

Biomedicine and Pharmacotherapy

Volumn 76, Issue , 2015, Pages 127-133

  Balaraman, Kaluvu ^a   Vieira, Nashira Campos ^a,b   Moussa, Fathi ^b   Vacus, Joël ^c   Cojean, Sandrine ^a   Pomel, Sébastien ^a   Bories, Christian ^a   Figadère, Bruno ^a   Kesavan, Ventikasamy ^d   Loiseau, Philippe M ^a  

^a UNIVERSITÉ PARIS SUD   (France)

^b University Paris Saclay   (France)

^c Drugabilis   (France)

^d INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

2 n propylquinoline; In vitro and in vivo antileishmanial activity; Pharmacokinetics; Toxicity

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2 N PROPYLQUINOLINE HYDROXYPROPYL BETA CYCLODEXTRIN; AMPHOTERICIN B; ANTILEISHMANIAL AGENT; MEGLUMINE ANTIMONATE; MILTEFOSINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; 2-PROPYLQUINOLINE; ANTIPROTOZOAL AGENT; BETA CYCLODEXTRIN DERIVATIVE;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; IC50; LEISHMANIA AMAZONENSIS; LEISHMANIA DONOVANI; LEISHMANIASIS; LIMIT OF DETECTION; MACROPHAGE; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PARASITE CLEARANCE; PARASITE LOAD; PRIORITY JOURNAL; TOTAL BODY WATER; VOLUME OF DISTRIBUTION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; HALF LIFE TIME; LEISHMANIASIS, VISCERAL; ORAL DRUG ADMINISTRATION; PARASITOLOGY; RAT; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; BETA-CYCLODEXTRINS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MICE; MICE, INBRED BALB C; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84949208518     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.10.028     Document Type: Article

References (19)

1. Mohapatra S. Drug resistance in leishmaniasis: newer developments. Trop. Parasitol. 2014, 4:4-9.
2. Mbongo N., Loiseau P.M., Billion M.A., Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother 1998, 42:352-357.
3. Seifert K., Matu S., Pérez-Victoria J.F., Castanys S., Gamarro F., Croft S.L. Characterisation of Leishmania donovani promastigotes résistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents 2003, 22:380-387.
4. Purkait B., Kumar A., Nandi N., Sardar A.H., Das S., Kumar S., et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 2012, 56:1031-1041.
5. Cojean S., Houzé S., Haouchine D., Huteau F., Lariven S., Hubert V., et al. Leishmania résistance to miltefosine associated with genetic marker. Emerg. Infect Dis. 2012, 18:704-706.
6. Fournet A., Barrios A.A., Munoz V., Hocquemiller R., Bruneton J. 2-substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrob. Agents Chemother. 1993, 37:859-863.
7. Fournet A., Ferreira M.E., Rojas de Arias A., Torrez de Ortiz S., Fuentes S., Nakayama H., et al. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob. Agents Chemother. 1996, 40:2447-2451.
8. Campos-Vieira N., Vacus J., Fournet A., Baudouin R., Bories C., Séon-Méniel B., et al. Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model. Parasite 2011, 18:333-336.
9. Fakhfakh M.A., Fournet A., Prina E., Mouscadet J.F., Franck X., Hocquemiller R., et al. Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral coinfections. Bioorg. Med. Chem. 2003, 11:5013-5023.
10. Nakayama H., Loiseau P.M., Bories C., Torrez de Ortiz S., Schinini A., Serna E., et al. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and viceral leishmaniasis. Antimicrob. Agents Chemother. 2005, 49:4950-4956.
11. Nakayama H., Desrivot J., Bories C., Franck X., Figadère B., Hocquemiller R., et al. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline agaisnt Leishmania donovani. Biomed. Pharmacother. 2007, 61:186-188.
12. Campos-Vieira N., Herrenknecht C., Vacus J., Fournet A., Bories C., Figadere B., et al. Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Biochem. Pharmacother. 2008, 62:684-689.
13. Desrivot J., Herrenknecht C., Ponchel G., Garbi N., Prina E., Fournet A., et al. Antileishmanial 2-substituted quinolines: in vitro behaviour towards biological components. Biomed. Pharmacother. 2007, 61:441-450.
14. Odds F.C. Synergy antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 2003, 52:1.
15. Cauchetier E., Paul M., Rivollet D., Fessi H., Astier A., Deniau M. Therapeutic évaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. Int. J. Parasitol. 2000, 30:777-783.
16. Yameogo J.B., Geze A., Choisnard L., Putaux J.L., Semde R., Wouessidjewe D. Progress in developing amphiphilic cyclodextrin-based nanodevices for drug delivery. Curr. Top. Med. Chem. 2014, 14:526-541.
17. Iglarz M., Baune B., Gantier J.C., Hocquemiller R., Farinotti R. Determination of 2-n-propylquinoline in mouse plasma and liver by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1998, 714:335-340.
18. Gopinath V.S., Rao M., Shivahare R., Vishwakarma P., Ghose S., Pradhan A., et al. Design, synthesis, ADME characterization and antileishmanial evaluation of novel substituted quinoline analogs. Bioorg. Med. Chem. Lett 2014, 24:2046-2052.
19. Gopinath V.S., Pinjari J., Dere R.T., Verma A., Vishwakarma P., Shivahare R., et al. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents. Eur. J. Med. Chem. 2013, 69:527-536.